EUVIMEDEUVIMED entdecken
Crossref

Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers

Zehui Zhou iD, Guizhen Zhou, Chuan Zhou, Zisheng Fan, Rongrong Cui, Yupeng Li iD, Rui Li, Yuejiao Gu, Huajie Li, Zhiming Ge, Xiaojia Cai, Bing Jiang und 4 weitere

Journal of Medicinal Chemistry · 23.03.2023 · 66 (6) · 4197-4214

DOI: 10.1021/acs.jmedchem.3c00075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.03.2023. Verfasst von Zehui Zhou und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Neoplasms. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Youth Innovation Promotion Association of the Chinese Academy of Sciences, National Natural Science Foundation of China, Lingang Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The linker moiety of a proteolysis-targeting chimera (PROTAC) molecule plays a critical role in modulating the degradation activity, target selectivity, and physico-chemical properties. However, the basics and underlying mechanisms of chemical modifications of the linker structure causing dramatic changes in the PROTAC degradation activity warrant further investigation. Herein, we report the design and characterization of a highly potent and selective SOS1 PROTAC ZZ151. After systematically modifying the linker length and composition, we observed that subtle modification of just one atom of the linker moiety of ZZ151 resulted in remarkable changes in the formation of the ternary complex and thus dramatically affected the degradation activities. ZZ151 quickly, specifically, and effectively induced SOS1 degradation; displayed potent antiproliferation activities against a broad panel of KRAS mutant-driven cancer cells; and showed superior anticancer activities in the KRASG12D- and G12V-mutant xenografts in mice. ZZ151 is a promising lead for developing new chemotherapies targeting KRAS mutants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)NeoplasmsHumansAnimalsMiceProteolysis

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
  • University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China.
  • Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • Masonic Cancer Center & Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.
  • School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.

ORCID-Profile: Zehui Zhou, Yupeng Li, Mingyue Zheng, Tianfeng Xu, Sulin Zhang

Förderung

  • Youth Innovation Promotion Association of the Chinese Academy of Sciences
  • National Natural Science Foundation of China
  • Lingang Laboratory

Zitieren

APA

Zhou, Z., Zhou, G., Zhou, C., Fan, Z., Cui, R., Li, Y., Li, R., Gu, Y., Li, H., Ge, Z., Cai, X., Jiang, B., Wang, D., Zheng, M., Xu, T., & Zhang, S. (2023). Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers. Journal of Medicinal Chemistry, 66(6), 4197-4214. https://doi.org/10.1021/acs.jmedchem.3c00075

Vancouver

Zhou Z, Zhou G, Zhou C, Fan Z, Cui R, Li Y, et al. Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers. Journal of Medicinal Chemistry. 2023;66(6):4197-4214. doi:10.1021/acs.jmedchem.3c00075

BibTeX
@article{Zhou2023,
  author = {Zhou, Zehui and Zhou, Guizhen and Zhou, Chuan and Fan, Zisheng and Cui, Rongrong and Li, Yupeng and Li, Rui and Gu, Yuejiao and Li, Huajie and Ge, Zhiming and Cai, Xiaojia and Jiang, Bing and Wang, Dan and Zheng, Mingyue and Xu, Tianfeng and Zhang, Sulin},
  title = {Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {6},
  pages = {4197--4214},
  doi = {10.1021/acs.jmedchem.3c00075}
}
Kostenlos starten →